Comparative protective effects of recombinant DNA andMycobacterium bovisbacille Calmette–Guérin vaccines againstM. aviuminfection
- 1 December 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 126 (3) , 482-487
- https://doi.org/10.1046/j.1365-2249.2001.01708.x
Abstract
A range of strategies are being explored to develop more effective vaccines against mycobacterial infection, including immunization with DNA plasmids encoding single mycobacterial bacterial genes and the use of recombinant live vectors based on the current vaccine, Mycobacterium bovis bacille Calmette–Guérin (BCG). We have compared these two approaches using a model of virulent M. avium infection, and the gene for the immunodominant 35 kDa protein which is shared by M. avium and M. leprae, but absent from BCG. Recombinant BCG over-expressing the M. avium 35 kDa protein (BCG-35) induced strong antigen-specific proliferative and interferon-γ (IFN-γ)-secreting T cell responses. These were comparable to those induced by a single immunization with a plasmid expressing the same antigen (DNA-35); however, repeat DNA-35 immunization evoked the strongest IFN-γ release. Immunization with BCG-35 significantly reduced the growth of virulent M. avium, although this effect was similar to that induced by wild-type BCG. Immunization with DNA-35 resulted in significantly greater (2 × log10) reduction in the growth of M. avium. Prime-boost strategies combining DNA-35 and BCG-35 increased the protective effect above that achieved by BCG-35, but they were not more protective than DNA-35 alone. Therefore, recombinant BCG-35 and BCG induced similar levels of protection in this model, and maximal protection against M. avium infection was attained by immunization with DNA encoding the 35 kDa protein.Keywords
This publication has 30 references indexed in Scilit:
- Priming by DNA Immunization Augments Protective Efficacy ofMycobacterium bovisBacille Calmette-Guerin against TuberculosisInfection and Immunity, 2001
- Protection against VirulentMycobacterium aviumInfection following DNA Vaccination with the 35-Kilodalton Antigen Is Accompanied by Induction of Gamma Interferon-Secreting CD4+T CellsInfection and Immunity, 2000
- Recombinant Bacille Calmette-Guerin Priming against MeaslesThe Journal of Infectious Diseases, 1995
- Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c miceMicrobiology, 1995
- Recombinant BCG strains expressing the SIV mac251nef gene induce proliferative and CTL responses against nef synthetic peptides in miceVaccine, 1995
- Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferiNature, 1994
- Treatment of Disseminated Disease Due to the Mycobacterium avium Complex in Patients with AIDSClinical Infectious Diseases, 1994
- Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.The Journal of Experimental Medicine, 1993
- Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccinesNature, 1991
- Prophylactic effect in mice of BCG vaccination against non-tuberculous mycobacterial infectionsTubercle, 1985